

TO: Central Fax COMPANY: USPTO
Jan 22 07 12:06p

4153335571

p.3

Application/Control Number: 10/726,198


Attorney Docket No. 3157.00011

January 22, 2007

addition to cancer that was originally claimed. However, per the conversation I had with Examiner Peter J. Redding on Friday, January 19, 2007 I hereby elect only the treatment of cancer for consideration for Claim 4.

Please note: Claim 6 originally referred to SEQ ID NO: 2 but the reference was incorrect. SEQ ID NO: 2 is *N*-terminally truncated galectin-3 that is corresponding to SEQ ID NO: 1 but with a cysteine added to the *N*-terminus to enable thiol-specific derivatization. Claim 6 is currently amended to correctly refer to SEQ ID NO: 3 that is the sequence of the intact recombinant human galectin-3 protein containing both Tyr-63 and Asp-241. As described exactly in the Specification and Claims 1, 2 and (amended) Claim 6, *N*-terminally truncated galectin-3 can be produced that possesses activity as a treatment for disease. The desired *N*-terminally truncated recombinant human galectin-3 molecules that include SEQ ID NO: 1 are composed of a specific subset of the amino acid residues comprising SEQ ID NO: 3 that is described in the Specification and that is defined in Claim 6.

Very respectfully yours,



Constance M. John, R.Ph., Ph.D.

MandalMed, Inc.

665 3rd Street, Suite 250

San Francisco, CA 94107

Tel.: 415-495-5570